HIGH-POTENCY SARS CORONAVIRUS 2 ANTIGEN AND VACCINE COMPOSITION COMPRISING SAME

The present invention has discovered an immunogen exhibiting higher immunogenicity against SARS coronavirus 2 by fusing a transmembrane domain peptide derived from an immune cell active LRRC24 protein, and has also confirmed that the neutralizing antibody was better formed in actual animal experimen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KIM, Chonsaeng, HWANG, In Su, KIM, Bum Tae, KWON, Young Chan, JEONG, Gi Uk, KU, Keunbon, LEE, Su Min, YOON, Gun Young, LEE, Sun Hee, AHN, Dae Gyun, SHIN, Hye Jin, KIM, Kyun Do, KIM, Hae Soo, KIM, Mi Hwa, KIM, Seong Jun
Format:	Patent
Sprache:	eng ; fre ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention has discovered an immunogen exhibiting higher immunogenicity against SARS coronavirus 2 by fusing a transmembrane domain peptide derived from an immune cell active LRRC24 protein, and has also confirmed that the neutralizing antibody was better formed in actual animal experiments. The present invention confirmed that excellent protective immunity was induced in all mice in the post-immunization challenge test to infect SARS coronavirus 2 after inoculation with the recombinant immunogen. In addition, the present invention confirmed that toxicity did not appear in the toxicity test. Using a recombinant immunogen showing such excellent results, it is possible to develop a vaccine for the prevention of SARS coronavirus 2, which poses a fatal risk. La présente invention a découvert qu'un immunogène présentant une immunogénicité supérieure vis-à-vis du SARS coronavirus 2 par fusion d'un peptide de domaine transmembranaire issu d'une protéine LRRC24 active de cellule immunitaire, et a également confirmé que l'anticorps neutralisant était mieux formé dans des expérimentations animales réelles. La présente invention a confirmé qu'une excellente immunité protectrice était induite chez toutes les souris dans le test de provocation post-immunisation consistant à infecter le SARS coronavirus 2 après inoculation avec l'immunogène recombinant. De plus, la présente invention a confirmé qu'une toxicité n'apparaissait pas dans le test de toxicité. Au moyen d'un immunogène recombinant présentant ces excellents résultats, il est possible de mettre au point un vaccin pour la prévention du SARS coronavirus 2, qui présente un risque mortel. 본 발명은 면역세포 활성 LRRC24 단백질 유래 세포막 투과 도메인 펩타이드를 융합시켜서 사스 코로나바이러스 2에 대해 더 높은 면역원성을 나타내는 면역원을 발굴하였고, 실제 동물실험에서도 중화항체가 더 잘 형성되었음을 확인하였다. 재조합 면역원 접종 후 사스 코로나바이러스 2를 감염하는 면역 후 공격시험에서도 모든 마우스에서 우수한 방어면역을 유도하는 것을 확인하였다. 또한, 독성시험에서도 독성이 나타나지 않는 것을 확인하였다. 이러한 우수한 결과를 보여주는 재조합 면역원을 이용하여 치명적인 위험을 나타내는 사스 코로나바이러스 2에 대한 예방을 위한 백신으로 개발할 수 있을 것이다.